These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Ibrutinib inhibits pre-BCR Kim E; Hurtz C; Koehrer S; Wang Z; Balasubramanian S; Chang BY; Müschen M; Davis RE; Burger JA Blood; 2017 Mar; 129(9):1155-1165. PubMed ID: 28031181 [TBL] [Abstract][Full Text] [Related]
26. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Burger JA; Landau DA; Taylor-Weiner A; Bozic I; Zhang H; Sarosiek K; Wang L; Stewart C; Fan J; Hoellenriegel J; Sivina M; Dubuc AM; Fraser C; Han Y; Li S; Livak KJ; Zou L; Wan Y; Konoplev S; Sougnez C; Brown JR; Abruzzo LV; Carter SL; Keating MJ; Davids MS; Wierda WG; Cibulskis K; Zenz T; Werner L; Dal Cin P; Kharchencko P; Neuberg D; Kantarjian H; Lander E; Gabriel S; O'Brien S; Letai A; Weitz DA; Nowak MA; Getz G; Wu CJ Nat Commun; 2016 May; 7():11589. PubMed ID: 27199251 [TBL] [Abstract][Full Text] [Related]
27. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo. Herman SE; Mustafa RZ; Jones J; Wong DH; Farooqui M; Wiestner A Clin Cancer Res; 2015 Oct; 21(20):4642-51. PubMed ID: 26089373 [TBL] [Abstract][Full Text] [Related]
28. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803 [TBL] [Abstract][Full Text] [Related]
29. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679 [No Abstract] [Full Text] [Related]
30. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164 [TBL] [Abstract][Full Text] [Related]
31. BTK Woyach JA; Ruppert AS; Guinn D; Lehman A; Blachly JS; Lozanski A; Heerema NA; Zhao W; Coleman J; Jones D; Abruzzo L; Gordon A; Mantel R; Smith LL; McWhorter S; Davis M; Doong TJ; Ny F; Lucas M; Chase W; Jones JA; Flynn JM; Maddocks K; Rogers K; Jaglowski S; Andritsos LA; Awan FT; Blum KA; Grever MR; Lozanski G; Johnson AJ; Byrd JC J Clin Oncol; 2017 May; 35(13):1437-1443. PubMed ID: 28418267 [TBL] [Abstract][Full Text] [Related]
32. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib. Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085 [TBL] [Abstract][Full Text] [Related]
33. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Fiorcari S; Maffei R; Audrito V; Martinelli S; Ten Hacken E; Zucchini P; Grisendi G; Potenza L; Luppi M; Burger JA; Deaglio S; Marasca R Oncotarget; 2016 Oct; 7(40):65968-65981. PubMed ID: 27602755 [TBL] [Abstract][Full Text] [Related]
34. Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. Martini V; Gattazzo C; Frezzato F; Trimarco V; Pizzi M; Chiodin G; Severin F; Scomazzon E; Guzzardo V; Saraggi D; Raggi F; Martinello L; Facco M; Visentin A; Piazza F; Brunati AM; Semenzato G; Trentin L Br J Haematol; 2017 Jul; 178(1):81-93. PubMed ID: 28419476 [TBL] [Abstract][Full Text] [Related]
35. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405 [TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML. Li S; Wu B; Zheng X; Wang C; Zhao J; Sun H; Sun X; Tang Z; Yuan H; Chen L; Ma X Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709 [TBL] [Abstract][Full Text] [Related]
40. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]